SK bioscience Co.,Ltd. (KRX:302440)

South Korea · Delayed Price · Currency is KRW

36,350

+1,200 (3.41%)

At close: Jun 24, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Pharmaceuticals	651.37B	267.55B	369.51B	456.73B	929.00B
Pharmaceuticals Growth	143.46%	-27.59%	-19.10%	-50.84%	-
Total	651.37B	267.55B	369.51B	456.73B	929.00B
Total Growth	143.46%	-27.59%	-19.10%	-50.84%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
America	98.37B	24.80B	185.96B	217.83B	48.41B
America Growth	296.68%	-86.66%	-14.63%	349.99%	-
Europe	401.38B	107.12B	21.20B	13.78B	184.50B
Europe Growth	274.68%	405.26%	53.88%	-92.53%	-
Asia	10.23B	3.55B	3.89B	651.33M	233.27M
Asia Growth	188.18%	-8.81%	497.76%	179.22%	-
South Korea	140.12B	131.49B	158.22B	224.16B	695.86B
South Korea Growth	6.56%	-16.89%	-29.42%	-67.79%	-
Middle East	1.27B	576.98M	231.61M	305.04M	-
Middle East Growth	119.92%	149.11%	-24.07%	-	-
Total	651.37B	267.55B	369.51B	456.73B	929.00B
Total Growth	143.46%	-27.59%	-19.10%	-50.84%	-